Skip to main content
Premium Trial:

Request an Annual Quote

Element Biosciences: Yaron Hakak

Sequencing firm Element Biosciences has appointed Yaron Hakak as senior VP of corporate and business development. Hakak was most recently CEO of Jumpcode Genomics. Prior to that he was a director of corporate and business development at Illumina, where he led a team supporting the company's life science, applied markets, and international businesses. He has also served as director of business development at Affymetrix. He holds a PhD ion molecular biology from the University of California, Berkeley, and a BS in biophysics from UC, San Diego.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.